Cornerstone Pharmaceuticals Inc. is saying little about its lead drug candidate, CPI-613, which entered its first Phase I/II human clinical trial in late 2008, but the company and its backers
believe they are developing a potentially game-changing class of new molecules and technology for delivering them. Its Altered Energy Metabolism Directed platform specifically utilizes the difference in cancer cells’ metabolic appetite to facilitate selective delivery of a novel small molecule (CPI-613 being the first example) into the cells’ mitochondria. Similarly the company’s
Emulsiphan leverages those same metabolic differences to deliver drugs specifically to the cancer cell cytoplasm.
1 Duncan Drive
Cranbury, NJ 08512
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.